Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Clinical Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients

View ORCID ProfileCameron Mura, View ORCID ProfileSaskia Preissner, View ORCID ProfileSusanne Nahles, View ORCID ProfileMax Heiland, View ORCID ProfilePhilip E. Bourne, View ORCID ProfileRobert Preissner
doi: https://doi.org/10.1101/2021.03.29.21253914
Cameron Mura
1School of Data Science and Department of Biomedical Engineering, University of Virginia, Charlottesville, VA; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Cameron Mura
  • For correspondence: Saskia.Preissner@charite.de cmura@virginia.edu
Saskia Preissner
2Department Oral and Maxillofacial Surgery, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Saskia Preissner
  • For correspondence: Saskia.Preissner@charite.de cmura@virginia.edu
Susanne Nahles
2Department Oral and Maxillofacial Surgery, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Susanne Nahles
Max Heiland
2Department Oral and Maxillofacial Surgery, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Max Heiland
Philip E. Bourne
1School of Data Science and Department of Biomedical Engineering, University of Virginia, Charlottesville, VA; USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Philip E. Bourne
Robert Preissner
3Institute of Physiology and Science-IT, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Philippstrasse 12, 10115 Berlin, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Robert Preissner
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

COVID-19 has spurred much interest in the therapeutic potential of repurposed drugs. A family of acid-reducing drugs, known as histamine H2 receptor antagonists (H2RA), competitively bind the H2R and block its stimulation by histamine; examples of such drugs are famotidine (e.g., Pepcid) and ranitidine (e.g., Zantac). A dense web of functionalities between histamine and H2RAs, on the one hand, and downstream cellular pathways, on the other hand, links disparate physiological pathways in gastrointestinal contexts (e.g., acid reduction) to the dysregulated inflammatory cas-cades (cytokine storm) underlying the pathophysiology of COVID-19. Is famotidine beneficial in treating COVID-19? This question remains unresolved, though not for lack of effort: over 10 studies have examined the potential therapeutic value of famotidine in COVID-19, but have found conflicting results (pro-famotidine, anti-famotidine, and neutral). Given the contradictory reports, we have undertaken the new analysis reported herein. Notably, studies published thus far rest upon substantially smaller datasets than drawn upon in the present work. We analyzed a cohort of 22,560 COVID-19 patients taking H1/H2 receptor antagonists, focusing on 1,379 severe cases requiring respiratory support. We analyzed outcomes for treatment with the H1RAs loratadine (e.g., Claritin) and cetirizine (e.g., Zyrtec), the H2RA famotidine, aspirin, and a famotidine & aspirin combination. For cases that reached the point of respiratory support, we found a significantly reduced fatality risk for famotidine treatment. We did not detect a benefit from dual-histamine receptor blockade (concurrently targeting H1 and H2 receptors). Notably, famotidine combined with aspirin did exhibit a significant synergistic survival benefit (odds ratio of 0.55). The relative risk for death decreased by 32.5%--an immense benefit, given the more than 2.6 million COVID-19-related deaths thus far. We found lower levels of serum markers for severe disease (e.g., C-reactive protein) in famotidine users, consistent with prior findings by others and with a role for famotidine in attenuating cytokine release. The large, international, multi-center retrospective study reported here, sampling over 250,000 COVID-19 cases, hopefully helps clarify the possible value of clinically-approved histamine antagonists such as famotidine. Given these findings, alongside the cost-effectiveness and mild side-effects of popular drugs like famotidine and aspirin, we suggest that further prospective clinical trials, perhaps utilizing the aspirin combination reported here, are advisable.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This work was supported by TRR295, KFO339, and DFG PR1562/1-1. Portions of this work were also supported by the University of Virginia School of Data Science and by NSF CAREER award MCB-1350957.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This work was reviewed by our IRB board (UVA IRB tracking ID #23100), who determined that this project as described does not meet the criteria for Human Subject Research. They stated that "No additional IRB submission/review is necessary to proceed with this project."

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflicts of interest: No author declares a conflict of interest.

Data Availability

Data can be made available to researchers upon request.

  • Abbreviations

    CI,
    confidence interval;
    CONSORT,
    Consolidated Standards of Reporting Trials;
    COVID-19,
    coronavirus disease 2019;
    OR,
    odds ratio;
    PPI,
    proton-pump inhibitor;
    RR,
    risk ratio;
    SARS-CoV-2,
    severe acute respiratory syndrome coronavirus 2;
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
    Back to top
    PreviousNext
    Posted April 05, 2021.
    Download PDF

    Supplementary Material

    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    Clinical Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    Clinical Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients
    Cameron Mura, Saskia Preissner, Susanne Nahles, Max Heiland, Philip E. Bourne, Robert Preissner
    medRxiv 2021.03.29.21253914; doi: https://doi.org/10.1101/2021.03.29.21253914
    Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
    Citation Tools
    Clinical Evidence for Improved Outcomes with Histamine Antagonists and Aspirin in 22,560 COVID-19 Patients
    Cameron Mura, Saskia Preissner, Susanne Nahles, Max Heiland, Philip E. Bourne, Robert Preissner
    medRxiv 2021.03.29.21253914; doi: https://doi.org/10.1101/2021.03.29.21253914

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Infectious Diseases (except HIV/AIDS)
    Subject Areas
    All Articles
    • Addiction Medicine (280)
    • Allergy and Immunology (579)
    • Anesthesia (139)
    • Cardiovascular Medicine (1943)
    • Dentistry and Oral Medicine (252)
    • Dermatology (184)
    • Emergency Medicine (333)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (697)
    • Epidemiology (11097)
    • Forensic Medicine (8)
    • Gastroenterology (622)
    • Genetic and Genomic Medicine (3164)
    • Geriatric Medicine (308)
    • Health Economics (561)
    • Health Informatics (2041)
    • Health Policy (862)
    • Health Systems and Quality Improvement (782)
    • Hematology (310)
    • HIV/AIDS (682)
    • Infectious Diseases (except HIV/AIDS) (12713)
    • Intensive Care and Critical Care Medicine (707)
    • Medical Education (317)
    • Medical Ethics (92)
    • Nephrology (334)
    • Neurology (2981)
    • Nursing (164)
    • Nutrition (463)
    • Obstetrics and Gynecology (589)
    • Occupational and Environmental Health (614)
    • Oncology (1549)
    • Ophthalmology (476)
    • Orthopedics (185)
    • Otolaryngology (266)
    • Pain Medicine (202)
    • Palliative Medicine (57)
    • Pathology (402)
    • Pediatrics (912)
    • Pharmacology and Therapeutics (381)
    • Primary Care Research (355)
    • Psychiatry and Clinical Psychology (2781)
    • Public and Global Health (5588)
    • Radiology and Imaging (1091)
    • Rehabilitation Medicine and Physical Therapy (631)
    • Respiratory Medicine (759)
    • Rheumatology (338)
    • Sexual and Reproductive Health (311)
    • Sports Medicine (289)
    • Surgery (343)
    • Toxicology (48)
    • Transplantation (159)
    • Urology (132)